During a meeting with his Chinese counterpart Wang Yi in Beijing, S Jaishankar said that India's decisions on Jammu and Kashmir are country's "internal" matter and the sole prerogative of the country.
Asserting that the legislative measures were aimed at promoting better governance and socio-economic development, Jaishankar also said there was no implication for either the external boundaries of India or the Line of Actual Control with China.
Adding that India was not raising any additional territorial claims, the External Affairs Minister said that Chinese concerns in this regard were misplaced.
He also conveyed that so far as the India China boundary question was concerned the two sides had agreed to a fair, reasonable and mutually acceptable settlement of the Boundary Question on the basis of the 2005 Political Parameters and Guiding Principles.
The Chinese Foreign Minister also referred to rising tensions between India and Pakistan as a result of these changes.
S Jaishankar emphasised that these changes had no bearing on Pakistan as it was an internal matter. It did not impact the LoC.
During his two-day visit, the External Affairs Minister also attended the 2nd meeting of the High Level Mechanism on Cultural and People-to-People Exchanges in Beijing.
During detailed discussions between Indian and Chinese foreign ministers, the two leaders discussed the full gamut of issues relating to the international situation, regional aspects and the bilateral relations including the visit of President Xi Jinping to India for the 2nd Informal Summit later this year and celebrating the 70th Anniversary of establishment of diplomatic relations next year.
The External Affairs Minister noted that since the Wuhan Informal Summit, there had been progress in the overall relationship.
The two countries agreed that maintenance of peace and tranquillity in border areas was essential for smooth development of their relations.
The economic relationship had seen some progress but the increasing trade deficit was a matter of concern.
It was emphasised that the Chinese side should take steps to address this issue including by enabling greater access for our pharmaceutical and IT products and services in the domestic Chinese market.